Prostate Cancer - Results from #360

Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: an ancillary study of the PROstate fractionated irradiation Trial - PROFIT. July 4, 2022

Cost-effectiveness analysis of short biparametric magnetic resonance imaging protocol in men at risk of prostate cancer. July 4, 2022

Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States. July 4, 2022

PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. July 3, 2022

Comparison of prostate cancer detection rate at targeted biopsy of hub and spoke centers mpMRI: experience matters. July 1, 2022

Two Specialists, Two Recommendations: Discordance between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations. July 1, 2022

Post-diagnostic Inflammatory, Hyperinsulinemic, and Insulin Resistant Diets and Lifestyles and the Risk of Prostate Cancer Progression and Mortality. July 1, 2022

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. July 1, 2022

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. July 1, 2022

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. July 1, 2022

Novartis Resumes Production and Delivery of Radioligand Therapy Medicines Ahead of Schedule June 30, 2022

Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia. June 30, 2022

The impact of radical prostatectomy on the social well-being of prostate cancer survivors: A qualitative meta-synthesis. June 30, 2022

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. June 30, 2022

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). June 30, 2022

WHO Classification of Tumours 5th Edition: Evolving Issues in Classification, Diagnosis and Prognostication of Prostate Cancer. June 30, 2022

Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. June 29, 2022

Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue. June 29, 2022

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence. June 29, 2022

Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. June 29, 2022

Page 19 of 1250

email news signup